Greater Manchester Mayor Andy Burnham has enthusiastically welcomed the opening of advanced laboratory facilities by biotechnology firm Vortex at Manchester Science Park, describing it as "fantastic news" for the region. The Cambridge-based company's expansion establishes a significant research, development, and commercial delivery centre in the heart of Manchester's thriving life sciences cluster.
A Strategic Move for Growth and Innovation
Vortex Biotech Holdings, which originated as a spin-out from the University of California, Los Angeles, specialises in pioneering liquid biopsy technology aimed at improving cancer treatments. The new Manchester site will not only serve as the company's European hub for fostering research partnerships but is also strategically designed to support future expansion into clinical trial operations and commercial product development.
This move represents a deliberate shift from London, positioning Vortex to capitalise on Greater Manchester's robust scientific ecosystem. The company maintains additional operational bases in Cambridge and California's Bay Area, underscoring its global reach and ambition.
Boosting the Local Economy and Healthcare
Andy Burnham emphasised the broader significance of this investment, stating: "Vortex Biotech's expansion at Manchester Science Park is a further vote of confidence in our life sciences sector. It strengthens our established cluster on the Oxford Road Corridor, where companies can access world-class research, clinical networks, and talent."
The Mayor highlighted that the new facility will generate high-skilled, high-value employment opportunities for residents across Greater Manchester. Simultaneously, it will advance diagnostic technologies with the potential to enhance cancer treatment outcomes on a global scale.
Access to Expertise and Infrastructure
Nigel Brooksby, Non-Executive Chairman at Vortex, explained the strategic rationale behind choosing Manchester Science Park. "Establishing our laboratory here is a key step in expanding collaborations with leading academic and clinical institutions," he said. "The Park's proximity to the University of Manchester, NHS Manchester Foundation Trust, and a dynamic life sciences ecosystem provides direct access to essential expertise, clinical samples, and translational infrastructure."
This environment is crucial for advancing liquid biopsy techniques—which enable earlier cancer detection through blood samples—into routine clinical practice.
Inward Investment Success
Joe Manning, Managing Director at MIDAS, Manchester's inward investment agency, noted that Vortex's relocation underscores the region's compelling offer to life sciences firms seeking growth. "Greater Manchester provides direct access to the University of Manchester's research capabilities, partnerships through the NHS Manchester Foundation Trust, and a talented workforce," he stated.
The expansion is expected to create numerous skilled roles in diagnostics, science, data analysis, and operations. Furthermore, Vortex has committed to nurturing local talent through apprenticeships and early-career development pathways, reinforcing the long-term benefits for the community.
This development solidifies Greater Manchester's reputation as a leading hub for medical innovation and economic investment in the North West.
